SIX1 and pulmonary fibrosis: One of the most challenging aspects of drug discovery for IPF is the identification of new targets using preclinical animal models of lung fibrosis that can be translated effectively (22, 62, 63), and this highlights the importance of our results, which show reduced progression of fibrosis and improved physiological lung function using the therapeutic deletion of Six1.